[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"attention-deficit-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:attention-deficit-disorder":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,53,76,141,165,190],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100619175","how-virtual-reality-can-help-neurodivergent-children-improve-their-attention-100619175",false,"NCT07341204","How Virtual Reality Can Help Neurodivergent Children Improve Their Attention","Improvement of Sustained Attention Through Immersive Virtual Reality in Neurodivergent Children","Attend-VR","Inclusion Criteria:\n\n* Clinical diagnosis of ASD, ADHD, SLD, or DCD confirmed by a licensed clinician or documented in medical\u002Feducational records (DSM-5 or equivalent).\n* Parent\u002Fguardian consent and participant assent (age-appropriate).\n* Ability to follow simple verbal instructions and to participate in 25-minute VR sessions twice weekly for 6 weeks.\n* Stable medication regimen for attention- or behavior-related medications for ≥4 weeks prior to baseline (or not taking such medications).\n* Visual and auditory ability adequate for VR tasks (with or without usual corrective lenses\u002Fhearing aids).\n* Availability to attend all scheduled sessions at the clinical site across the 6-week period.\n\nExclusion Criteria:\n\n* History of photosensitive epilepsy or any uncontrolled seizure disorder.\n* Severe intellectual disability or severe communication impairment that prevents understanding\u002Fparticipation (e.g., non-responsive to simple commands required by the VR tasks).\n* Severe visual, auditory, or motor impairment that prevents safe or functional use of the VR system (e.g., inability to hold controllers or view the headset even with correction).\n* Recent (within 6 months) significant brain injury or neurosurgery. Significant history of motion sickness, severe vestibular disorder, or prior intolerance to immersive VR.\n* Any medical or implanted device contraindicated for VR\u002Fheadset use (if applicable).",true,"ALL","9 Years","18 Years",{"count":22,"type":23},40,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this study is to determine whether playing a virtual reality (VR) game can help neurodivergent children pay attention for extended periods. The study includes children ages 9 to 18 who have autism, ADHD, learning differences, or movement coordination challenges. The program lasts for 6 weeks. During this period, children will play a VR game twice per week, with each session lasting 25 minutes.",[29,30,31,32],"Autism","Autism Disorder","ADHD - Attention Deficit Disorder With Hyperactivity","Attention Deficit Disorder",[34,35,36,37,38,39],"attention","impulsivity","distractability","focus","VR","Immersive Virtual Reality","NOT_YET_RECRUITING","2026-01-06",{"date":43,"type":44},"2026-01-14","ACTUAL",{"date":46,"type":23},"2026-02-02",{"date":48,"type":23},"2026-04-06",{"name":50,"class":51},"New York Institute of Technology","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":18,"minAge":20,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":24,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":52},"100466476","home-based-transcranial-direct-current-stimulation-tdcs-for-treatment-of-attention-deficithyperactivity-disorder-adhd-100466476","NCT05354232","Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit\u002FHyperactivity Disorder (ADHD)","Inclusion Criteria:\n\n1. Male and female outpatients 18-65 years of age\n2. A diagnosis of ADD\u002FADHD or meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria.\n\nExclusion Criteria:\n\n1. Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck, brain stimulators, vagus nerve stimulators, VP shunt, pacemakers, pregnancy.\n2. Active substance dependence (except for tobacco).\n3. Pregnant or nursing females.\n4. Inability to participate in testing procedures.\n5. Premorbid neurological conditions (including neurovascular and neurodegenerative diseases such as traumatic brain injury, stroke, Parkinson's, AD and other dementias) and severe psychiatric disorders (bipolar disorder, schizophrenia).","65 Years",{"count":61,"type":23},60,[26],"The investigators are investigating whether home-based tDCS over the course of four weeks can improve ADHD symptom severity and improve dysexecutive functioning (cognitive control). Further, the investigators are investigating whether there is a dose-dependent response to tDCS.",[32,65],"Attention Deficit Disorder With Hyperactivity","RECRUITING","2025-12-05",{"date":69,"type":44},"2025-12-12",{"date":71,"type":44},"2022-07-01",{"date":73,"type":23},"2026-05",{"name":75,"class":51},"Massachusetts General Hospital",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":18,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":24,"phases":88,"briefSummary":89,"conditions":90,"keywords":106,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":4},"100577382","the-primary-objective-of-this-study-is-to-determine-whether-positively-framed-information-pfi-on-side-effects-compared-to-negatively-framed-and-extensive-information-nfi-can-reduce-the-number-and-severity-of-reported-adverse-events-caused-by-adhd-medication-in-children-aged-7-to-17-years-100577382","NCT06797570","The Primary Objective of This Study is to Determine Whether Positively Framed Information (PFI) on Side Effects, Compared to Negatively Framed and Extensive Information (NFI) Can Reduce the Number and Severity of Reported Adverse Events Caused by ADHD Medication in Children Aged 7 to 17 Years.","Nocebo Effecten Verminderen in Kinderen Met ADHD: the NOVA Study","NOVA","Inclusion Criteria:\n\n* Children aged 7 to 17 years\n* Recently diagnosed with ADHD or ADD by a psychologist\n* Desire to start ADHD\u002FADD medication expressed by both the child and the parents\n\nExclusion Criteria:\n\n* Previous use of stimulants\n* 1st or 2nd degree family member using stimulants for ADHD\u002FADD within the last two years","7 Years","17 Years",{"count":87,"type":23},130,[26],"The goal of this randomized controlled care evaluation is to determine whether positively framed and concise information (PFI), compared to negatively framed and extensive information (NFI) about adverse events can reduce the number and severity of reported adverse events caused by ADHD medication in children aged 7 to 17 years. The main questions it aims to answer are:\n\n1. Does PFI reduce the percentage of children suffering from decreased appetite in the first 4 weeks after starting medication compared to NFI?\n2. Does PFI reduce the total number of adverse events compared to NFI?\n3. Does PFI lower the total score on the Pittsburgh Side Effects Rating Scale (PSRS) compared to NFI?\n4. Does PFI lead to higher parental satisfaction with the explanation of adverse events compared to NFI?\n5. Does PFI reduce the number of patients who discontinue medication due to adverse events compared to NFI?\n6. Does PFI decrease the number of patients needing melatonin for sleeping problems due to the use of methylphenidate compared to NFI?\n7. What is the relationship between baseline factors such as age, ADHD or ADD diagnosis, and gender on the number of adverse events?\n\nResearchers will compare children who receive positively framed, concise information (PFI) to those who receive negatively framed, detailed information (NFI) to determine if the framing of information affects the prevalence and severity of reported side effects, medication adherence, and parental satisfaction.\n\nParticipants in this study will:\n\n* Be randomly assigned to receive either PFI or NFI about the side effects of methylphenidate.\n* Start taking methylphenidate according to standard care protocols.\n* Complete a Pittsburgh Side Effects Rating Scale (PSRS) questionnaire 4 weeks after starting medication to report any adverse events and their severity.\n* Parents will provide feedback on satisfaction with the explanation of side effects using a short questionnaire.\n\nThis trial aims to inform best practices for communicating potential side effects to improve medication adherence and the overall treatment experience for children with ADHD and their families.",[32,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105],"Attention Deficit Disorder (ADD)","Attention Deficit Disorder with Hyperactivity","ADHD","ADD","ADHD-not Other Specified","ADHD or ADHD Traits","ADHD Predominantly Hyperactivity Type","ADHD Predominantly Inattentive Type","ADHD with Sleep Onset Insomnia","ADHD, ADD","ADHD, Predominantly Hyperactive - Impulsive","ADHD, Predominantly Inattentive Type","Hyperactivity","Hyperactivity Disorder","Inattention",[107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131],"attention deficit hyperactivity disorder","attention deficit disorder","hyperactivity","inattention","adverse drug reaction","adverse events","side effects","nocebo effect","medication side effects","patient education","communication methods","communication strategies","pediatric care","parental satisfaction","pharmacological treatment","treatment","medication adherence","medication","child health","side effect management","treatment compliance","pediatric pharmacology","positive framing","negative framing","side effect reporting","2025-01-22",{"date":134,"type":44},"2025-01-28",{"date":136,"type":23},"2025-01-25",{"date":138,"type":23},"2027-01-06",{"name":140,"class":51},"St. Antonius Hospital",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":17,"sex":18,"minAge":20,"maxAge":59,"enrollmentInfo":148,"targetDuration":4,"studyType":24,"phases":150,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":52},"100535161","phase-4-a-trial-of-dyanavel-xr-in-treating-co-occurring-fatigue-symptoms-in-adults-with-attention-deficit-hyperactivity-disorder-adhd-100535161","NCT06248229","A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).","A Single Center, Flexible-Dose, 10-Week, Randomized, Double-Blinded, Placebo-Controlled, Clinical Trial To Study The Efficacy Of Dyanavel XR In Treating Co-Occurring Fatigue In Adults With Attention Deficit\u002FHyperactivity Disorder (ADHD)","Inclusion Criteria:\n\n* At screening, all subjects must have a Fatigue Symptom Inventory average score on both of the interference and severity scales greater than 3.\n* At screening, all subjects must score in the clinically significant range on the ADHD-RS-IV, meaning a score greater than 36.\n* At screening, all subjects must meet criteria for an ADHD diagnosis as determined by the SCID-5 ADHD module.\n* All subjects must be 18-65 years of age at the time of consent.\n* All sexually active males or females of child baring potential must agree to practice two different methods of birth control or remain abstinent during the course of the trial. Methods of birth control or contraception will be logged. Male and female contraception will be continued throughout the study and for 30 days after study discontinuation. Women of childbearing potential must test negative for pregnancy at the Screening Visit.\n* All subjects must live within the state of Michigan during the duration of the trial or be able to commute to the study site from a neighboring state with no more than a 50 mile one-way driving distance.\n* All subjects must be able to swallow intact tablets.\n* Subjects, in the opinion of the investigator, must be able to understand and comply with protocol requirements- including assessments, prescribed dosage regimens, and discontinuation of concomitant medications.\n* All subjects must have a minimum level of intellectual functioning without evidence of significant general intellectual deficit, as determined by the primary investigator. Specific learning disorders will not be considered general intellectual deficits.\n* All subjects must be able to provide written, personally signed and dated informed consent to participate in the study in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 and applicable regulations before completing any study related procedures.\n* All subjects must be fluent in English and have a degree of understanding sufficient to communicate suitably with the primary investigator and the study coordinator.\n* Subjects must have a negative drug screen for methamphetamine, cocaine and other illicit drugs (illegal for recreational use in the State of Michigan) excluding cannabis due to legality of cannabis in Michigan. Subjects with a positive drug screen for confirmed prescription or over the counter use of medications will require the necessary washout per PI instruction. Subjects who test positive for any prohibited medications per PI may be permitted with PI approval. Re-tests will not be allowed for a positive screen of an illicit drug.\n* All subjects must score at or above a 4 on the CGI-S at screening\n\nExclusion Criteria:\n\n* Subjects must not be an immediate family of the Investigator or others directly affiliated with the study.\n* Subjects must not have received treatment with a drug that has not received regulatory approval or participated in a clinical trial within 30 days prior to screening.\n* Subjects must not have medical complications arising from being severely underweight or overweight.\n* Subjects must not have a current comorbid psychiatric disorder that is uncontrolled and associated with significant symptoms or that requires a prohibited medication or behavioral modification program. Comorbid psychiatric diagnoses will be assessed during a psychiatric intake and scoring of the SCID and MINI. The Investigator will review on a case by case basis.\n* Subjects must not currently be considered a suicide risk (as determined by the primary investigator and assessed by the C-SSRS). They must not have made a suicide attempt within the past two years. They cannot have current suicidal ideation with intent and plan to act, or current suicidal behavior.\n* Subjects must not have a history of substance abuse or drug dependence according to DSM-5 criteria currently or within one year prior to study participation, excluding nicotine and caffeine. This is determined through clinical history and symptom checklist to be obtained at visit 1.\n* Subjects must not test positive for an illicit substance at the time of screening.\n* Subjects must not have a serious chronic or acute unstable medical condition or illness, including cardiovascular, renal, hepatic, respiratory, or hematologic illness, narrow angle glaucoma, or other unstable medical or psychiatric conditions that in the opinion of the Investigator would compromise participation or would likely lead to hospitalization during the duration of the study. Subjects with a history of intellectual impairment or a severe learning disability are also excluded.\n* Subjects must not have a history of seizure disorder (other than infantile febrile seizures), any tic disorder, current diagnosis and\u002For family history of Tourette's disorder.\n* Subjects must not have a history of organic heart disease including coronary artery disease, past myocardial infarction, angina, arrhythmias, congestive heart failure, valvular heart disease and congenital heart disease.\n* Subjects must not be likely (as assessed by the primary investigator) to add psychotropic medications, apart from their current regimen or the drug under study, to their treatment regimen during the course of the study.\n* Subjects must not have been previously enrolled in this study.\n* Subjects must not anticipate relocation outside the geographic range of the investigative site during participation in the study. Subjects must not have extended travel plans inconsistent with the recommended visit intervals.\n* Subjects must not be taking any excluded medications that cannot be discontinued prior to beginning treatment with study medication. Subjects' medical history will be reviewed by the PI and current prescription regimen will be reviewed for wakefulness-promoting drugs including CNS stimulants, histaminergic, noradrenergic and dopaminergic medications, as well as CYP2D6 inhibitors. The primary investigator will determine on a case by case basis if concomitant use of the patient's current prescriptions would affect response to Dyanavel XR. Stimulant medications must be washed out prior to baseline (methylphenidate or amphetamine based).\n* Subjects must not have a known hypersensitivity, allergy intolerance or documented history of non-responsivity to amphetamine-based medications.\n* Subjects who, in the opinion of the Investigator, are unsuitable in any other way to participate in the study.\n* Subjects who have taken an MAOI within 14 days of the beginning of the study.\n* Subjects currently taking a medication regimen that would otherwise likely interfere with the efficacy of Dyanavel XR or the integrity of study results as determined on a case by case basis by the primary investigator.\n* Subjects who have recently (within the previous 3 months) been on CNS stimulant medications",{"count":149,"type":23},50,[151],"PHASE4","The goal of this clinical trial is to study the impact of Dyanavel on co-occuring fatigue in adults with Attention Deficit\u002FHyperactivity Disorder. The main question it aims to answer is whether Dyanavel XR leads to a statistically significant reduction in fatigue compared to placebo, as measured by the Fatigue Symptom Inventory.",[154,155,32],"Fatigue","Attention Deficit Hyperactivity Disorder","2024-11-18",{"date":158,"type":44},"2024-11-21",{"date":160,"type":44},"2024-09-01",{"date":162,"type":23},"2026-12-01",{"name":164,"class":51},"Rochester Center for Behavioral Medicine",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":18,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":24,"phases":176,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":4},"100561774","study-of-the-efficacy-of-sulforaphane-in-children-aged-6-to-12-with-attention-deficit-disorder-with-or-without-hyperactivity-100561774","NCT06594536","Study of the Efficacy of Sulforaphane in Children Aged 6 to 12 With Attention Deficit Disorder With or Without Hyperactivity","SulfoTDAH","Inclusion Criteria:\n\n* Children aged 6 to 12\n* Diagnosis of ADHD according to DSM-5 criteria (Diagnostic and Statistical Manual of Mental Disorders)\n* Followed or hospitalised in an investigating centre\n* Consent of holders of parental authority\n* Patient covered by health insurance (social security or CMU)\n* Patients able to swallow capsules\n\nExclusion Criteria:\n\n* Allergy to broccoli\n* Psychotropic treatment including methylphenidate in the month prior to inclusion\n* Ongoing psychotherapeutic and\u002For psycho-educational treatment specific to ADHD\n* ASD (Autism Spectrum Disorder) according to DSM-5 criteria, intellectual disability (IQ\\\u003C 80)\n* Chronic neurological disease, epilepsy\n* Holders of parental authority under guardianship or curatorship\n* Previous intake of sulforaphane\n* Known hypothyroidism or current thyroid treatment\n* Participation in other interventional research involving the human person or being within the exclusion period following previous research involving the human person, where applicable\n* Patient under AME (state medical aid)","6 Years","12 Years",{"count":175,"type":23},70,[26],"ADHD is a neurodevelopmental disorder. It is the most common neurodevelopmental disorder in children and adolescents. Its prevalence is estimated at 5.9% in this population. The symptoms of ADHD combine attention deficit with behavioural disorders such as hyperactivity and impulsivity. Current treatment for ADHD is based on psychotherapeutic and psychoeducational measures aimed at improving behaviour and its impact on the family, social and school environment. Drug treatments may also be used, depending on the impact of the disorder and the effectiveness of alternative treatments. Psychostimulants such as amphetamine derivatives and methylphenidate are around 80% effective.\n\nSulforaphane is an active substance derived from broccoli that has already been tested in the treatment of other neurodevelopmental disorders. The main hypothesis is that sulforaphane is effective in treating the symptoms of Attention Deficit Disorder with or without Hyperactivity (ADHD) in children.",[32],[180],"Sulforaphane","2024-09-10",{"date":183,"type":44},"2024-09-19",{"date":185,"type":23},"2024-12-01",{"date":187,"type":23},"2026-09-01",{"name":189,"class":51},"Assistance Publique - Hôpitaux de Paris",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":18,"minAge":197,"maxAge":173,"enrollmentInfo":198,"targetDuration":4,"studyType":24,"phases":200,"briefSummary":201,"conditions":202,"keywords":208,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":52},"100531005","weighted-blankets-for-sleep-disturbance-among-children-with-adhd-100531005","NCT06194162","Weighted Blankets for Sleep Disturbance Among Children With ADHD","Impact of Weighted Blankets on Sleep Disturbance Among Children With Attention Deficit Hyperactivity Disorders: A Pragmatic Randomised Trial","Inclusion Criteria:\n\n1. Signed informed consent.\n2. Age 5-12 years (both included) at randomization.\n3. Primary diagnosis of ADHD according to ICD-10 code F90.0, F90.1, F90.9 or F98.8.\n4. Comorbidities are allowed.\n5. Participated in a usual care sleep hygiene program managed by clinicians without effect within 6 months prior to enrollment.\n6. If on ADHD medication or\u002Fand melatonin\u002Fsleep medication the dose must be stable, at least two weeks prior to enrollment.\n7. The child and caregiver have adequate mastery of the Danish language.\n\nExclusion Criteria:\n\n1. Have used any type of medical device class 1 weighted blanket before.\n2. Any diagnosed diseases that markedly compromises the participant's ability to adhere to the intervention (like mental retardation, severe underweight, chronic respiratory or circulatory conditions, surgical implants, osteoporosis).\n3. Another member of the household enrolled in the trial.","5 Years",{"count":199,"type":23},340,[26],"Many children with ADHD suffer from sleep disorders and dysfunction, which may affect development and well-being. According to the clinicians, some children find relief from restlessness and difficulty sleeping by using weighted blankets which have been proposed to reduce restlessness and stress via sensory integration and to calm the child by stimulating the sense of touch, muscles and joints. However, evidence for an effect on sleep is scarce, and only one RCT has investigated the effect of weighted blankets among children with ADHD. Using a RCT design, the aim is to investigate the effect on sleep disorders and dysfunction in children with ADHD aged 5-12 years by (1) using a weighted blanket during night and daytime in addition to usual treatment, compared to (2) usual treatment and a non-weighted sham blanket, with the primary outcome being differences in total sleep time. Results will support health- and social professionals who are involved in the treatment of children with ADHD.",[203,155,204,205,32,206,207],"Attention-deficit Hyperactivity","Neurodevelopmental Disorders","Sleep Disturbance","Hyperkinetic Conduct Disorder","Attention-Deficit Hyperactivity Disorder, Unspecified Type",[93,209,210,211,205,94,212],"weighted blanket","Children","Randomised controlled trial","Functional impairment","2024-01-12",{"date":215,"type":44},"2024-01-17",{"date":217,"type":44},"2024-01-01",{"date":219,"type":23},"2028-08-01",{"name":221,"class":51},"University Hospital Bispebjerg and Frederiksberg"]